Search Results for “Amgen” – Page 5 – media

Breaking news! The CEO of a global orthopedic giant may be dismissed

Recently, according to the British “Mail on Sunday report”, the global orthopedic giant Smith & Nephew has received a severe warning from shareholders due to its poor performance. Smith & Nephew’s shareholders have lost patience with the strategic development speed of CEO Deepak Nath and declared that if the company’s performance cannot be improved, Deepak Nath will be dismissed and Smith & Nephew will also face the split of the orthopedic department. It is reported that Smith & Nephew’s stock price has fallen by as much as 44% in the past five years. As this year’s performance has not yet “cleared up”, shareholders’ emotions are difficult to appease, further putting pressure on Deepak Nath. Century-old enterprise faces crisis Smith & Nephew was founded in the UK in 1856. This old company with a long history of more than 100 years has three main businesses: orthopedics, sports medicine and otolaryngology, and ...
- Source: drugdu
- 47
- November 16, 2024
Global orthopedic giant CEO may be dismissed

Recently, according to the Mail on Sunday report in the UK, global orthopedic giant Smith&Nephew has received a stern warning from shareholders due to poor performance. Smith&Nephew’s shareholders have lost patience with CEO Deepak Nath’s strategic development speed, claiming that if the company’s performance cannot be improved, Deepak Nath will be dismissed and Smith&Nephew will also face the splitting of its orthopedic department internally. It is reported that the stock price of Xerox Hui has dropped by up to 44% in the past five years. With this year’s performance still not “clear up”, the emotions of shareholders are difficult to calm, further putting pressure on Deepak Nat. Century old enterprises face crisis Shi Lehui was founded in the UK in 1856, a well-established company with over a hundred years of history. Its main businesses include orthopedics, sports medicine and otolaryngology, and advanced wound management. Currently, Shi Lehui is at the ...
- Source: drugdu
- 51
- November 15, 2024
Another GLP-1 drug king, is it on the way?

Recently, the Q3 financial reports of MNCs have been released one after another, and some are happy and some are sad. When a number of MNCs began to lower their full-year EPS, Amgen’s Q3 financial report earnings gave a high score answer sheet. Among them, Amgen’s total revenue in the third quarter increased by 23%, and its GAAP net earnings per share (EPS) increased by 62% year-on-year, from US$3.22 to US$5.22. What is more imaginative is that with the data catalysis of the new macromolecular weight loss drug AMG133, this macromolecular antibody that goes against the grain and antagonizes GIPR may become Amgen’s next gold mine. According to Amgen’s Q3 2024 financial report, the most significant year-on-year growth is LUMAKRAS (AMG510) – a targeted drug for KRASG12C mutation-positive lung cancer. The sales ceiling of this gene mutation in European and American countries will be much higher than that in Asian ...
- Source: drugdu
- 60
- November 6, 2024
Domestic TCE polyclonal antibodies are “surging”

MNCs are hunting for domestic molecules and have already involved the field of TCE polyclonal antibodies. On October 29, GlaxoSmithKline announced the acquisition of Enmu Bio’s CD19 and CD20 targeted T cell engager CMG1A46, including a $300 million advance payment and $550 million in potential milestone payments. Not long ago in August, Merck also bought Tongrun Bio’s CD3xCD19 bispecific antibody CN201 with a down payment of $700 million and a milestone payment of $600 million. The direction of the giants is also relatively consistent: betting on the autoimmune market. At present, the core “battlefield” of TCE polyclonal antibodies is tumors. TCE polyclonal antibodies are relatively special. One end (or two ends) is connected to TAA (tumor-associated antigen) to locate tumor cells, and the other end is connected to the CD3 epitope of T cells to activate T cells and exert the tumor-killing effect of T cells. In the field of ...
- Source: drugdu
- 53
- November 2, 2024
the wind rises, accelerates, and accelerates again

The development story of tumor drugs is always so similar: the early stage may be endless suffering, but after countless failures and dashed hopes, once there is a breakthrough, the progress is often unexpected. This is the development of drugs for the treatment of small cell carcinoma (SCLC). SCLC was first discovered about 100 years ago, but it was not until 1968 that the medical community discovered its neuroendocrine origin and finally clearly distinguished it from other lung cancers. In the 1980s, the treatment of platinum-containing chemotherapy combined with chest radiotherapy gradually became clear and became the basic treatment for small cell lung cancer. Although the combination of etoposide and carboplatin/cisplatin (EP) has been the standard treatment for SCLC until now; but we can also clearly see that the battle against small cell lung cancer has entered an accelerated stage. In May of this year, Amgen’s DLL3/CD3 dual antibody Tarlatamab ...
- Source: drugdu
- 54
- November 1, 2024
Latest! AstraZeneca announces 10 billion yuan cooperation

On October 7, AstraZeneca and CSPC Pharmaceutical Group signed an exclusive licensing agreement, and AstraZeneca will obtain CSPC Pharmaceutical Group’s preclinical candidate small molecule drug YS2302018. The transaction amount hit a new high. According to the agreement, CSPC Pharmaceutical Group will receive an advance payment of US$100 million and is entitled to receive potential development milestone payments of up to US$370 million and potential sales milestone payments of up to US$1.55 billion, as well as tiered sales commissions calculated based on the annual net sales of the product (the total transaction amount exceeds RMB 10 billion at the current exchange rate). YS2302018 is a preclinical innovative small molecule lipoprotein (a) (Lp(a)) inhibitor used to develop new lipid-lowering therapies, as well as monotherapy or combination therapy for a variety of cardiovascular diseases, including in combination with the oral small molecule PCSK9 inhibitor AZD0780. Lpa is an important target in the field ...
- Source: drugdu
- 81
- October 10, 2024
PCSK9 antibody marketing application received notification

On September 29, 2024, two acceptance numbers for Junshi Biosciences’s PCSK9 antibody marketing application were notified, indicating that they have not been approved (possibly due to voluntary withdrawal or pending approval). In April 2023, Junshi Biosciences received 4 acceptance numbers for its PCSK9 antibody market application, of which 2 were notified this time, and the other 2 have not yet received results. Four acceptance numbers involve two specifications (pre filled syringes, pre filled automatic syringes) and two indications. This two notifications indicate that a certain specification or indication has not been approved. The competition for PCSK9 targets is particularly fierce. In addition to antibodies from Amgen and Sanofi, PCSK9 antibodies from Sinovac Biotech and PCSK9 siRNA from Novartis have already been approved for marketing. Among them, Novartis’ PCSK9 siRNA only needs to be administered once every six months. For this target, there are more differentiated products under development, including Merck’s ...
- Source: drugdu
- 73
- October 9, 2024
The second half of the battle to defend the Medicine King

Recently, Astellas announced that Japan’s MHLW has approved its ADC drug ennozumab PADCEV and Merck’s K drug as a first-line combination therapy for adult patients with fundamentally unresectable urothelial cancer. With excellent data, this combination treatment regimen was approved by the Japanese MHLW in such a short time after Merck announced on September 4 that it had been approved by the European Commission (EC) as a first-line therapy. However, sporadic victories cannot conceal the plight of K-drugs. For the pharmaceutical industry, the biggest hot spot in the past two weeks is definitely the announcement by Kangfang Biologics on September 8 that ivocilimab has become the world’s first and only single-drug head-to-head phase III clinical study to prove that its efficacy is significantly better than that of pabrolib. The drug Zizumab. On the day the results were announced, Merck’s stock price fell in response, and the dilemma was obvious. Under the ...
- Source: drugdu
- 85
- September 30, 2024
Another new COPD drug is coming

On September 6, GlaxoSmithKline (GSK) announced that its Phase 3 MATINEE study of its IL-5 antibody Nucala (mepolizumab) in the treatment of COPD achieved positive results. Compared with the placebo group, the Nucala treatment group achieved a statistically significant reduction in the annualized rate of moderate to severe exacerbations, but specific data have not yet been released. Two months ago, two COPD drugs with new mechanisms: ensifentrine and dupilumab were approved for marketing in the United States and Europe, refreshing the treatment model of this severe respiratory disease. Mepolizumab is expected to join this new round of competition. COPD: The third leading cause of death in humans Chronic obstructive pulmonary disease (COPD), referred to as COPD, is a common, preventable and treatable heterogeneous disease. According to statistics from the World Health Organization, COPD has become the third leading cause of death in humans, with about 11% of people dying from ...
- Source: drugdu
- 67
- September 14, 2024
Treatment of small cell lung cancer enters a period of accelerated breakthroughs

In the field of tumors, any breakthrough is not easy. Although humans have discovered cancer for a long time, chemotherapy has long been the core treatment method. Of course, after countless failures and dashed hopes, once there is a breakthrough, the progress is often unexpected. For example, after decades of silence, the treatment of small cell carcinoma seems to have ushered in a period of accelerated breakthroughs. On August 15, AstraZeneca announced that its drug durvalumab has been accepted by the FDA for the indication of limited small cell lung cancer (LS-SCLC). If approved for marketing, this will be the first immunotherapy in 40 years to show survival benefits in this field, representing an important breakthrough. For limited-stage SCLC, the current first-line treatment is still chemoradiotherapy, especially the treatment of cisplatin combined with etoposide, which occupies an absolute dominant position in treatment. Amgen has also made progress in the field ...
- Source: drugdu
- 113
- August 31, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.